Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats

Overexpression of P-glycoprotein (Pgp) increases multidrug resistance (MDR) in cancer, which greatly impedes satisfactory clinical treatment and outcomes of cancer patients. Due to unknown pharmacokinetics, the use of Pgp inhibitors to overcome MDR in the clinical setting remains elusive despite pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yan, Shen, Jacson K., Choy, Edwin, Zhang, Zhan, Mankin, Henry J., Hornicek, Francis J., Duan, Zhenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860631/
https://www.ncbi.nlm.nih.gov/pubmed/27157103
http://dx.doi.org/10.1038/srep25659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860631/
https://www.ncbi.nlm.nih.gov/pubmed/27157103
http://dx.doi.org/10.1038/srep25659

Ejemplares similares